Pharma: Page 63
-
Permission granted by BioNTech SE
Coronavirus vaccines speed ahead, but experts fear not everyone will take them
Gaining trust will be a tough task as public health officials gear up for one of the biggest immunization campaigns in decades.
By Jonathan Gardner • July 23, 2020 -
Shutterstock.com/fizkes
Sponsored by ZSPharma's KAM programs have never been more relevant
As companies begin to understand how priorities have shifted during the pandemic, KAM teams can devise appropriate solutions that fulfill their customers' unmet needs.
By Mike Moorman & Namita Powers • July 23, 2020 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Permission granted by BioNTech SE
US to pay nearly $2B for supply of Pfizer, BioNTech coronavirus vaccine
The order, which would secure 100 million doses for the U.S., is the largest made to date under the Trump administration's "Warp Speed" project.
By Ned Pagliarulo • July 22, 2020 -
Brian Tucker/BioPharma Dive
Coronavirus vaccine developers make case to Congress they can win public's trust
While developing a safe and effective vaccine remains the chief challenge, lawmakers grilled pharma officials on how any successful shot would be fairly priced and distributed.
By Ben Fidler • July 21, 2020 -
Permission granted by University of Maryland School of Medicine
Pfizer and BioNTech coronavirus vaccine gets boost from German data
As the race to bring a vaccine to market accelerates, the companies unveiled new clinical results and a deal that promises the U.K. 30 million doses of a successful shot.
By Jonathan Gardner • July 20, 2020 -
GSK invests in mRNA vaccines through deal with CureVac
While CureVac's coronavirus work is excluded from the deal, GSK said the biotech's platform should complement its existing vaccine technology and provide greater access to manufacturing.
By Jacob Bell • July 20, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
Oxford coronavirus vaccine spurs immune responses, appears safe on first look
The vaccine, from the University of Oxford and AstraZeneca, is backed with more funding from governments and non-profit groups than any other in development.
By Ben Fidler • July 20, 2020 -
Sanofi, on the lookout for acquisitions, may have spotted a target
A Bloomberg report names Principia Biopharma, a biotech with an existing partnership with Sanofi, among the U.S. companies that the French pharma is evaluating for possible deals.
By Jacob Bell • July 17, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from Flickr.
J&J, on the cusp of starting coronavirus vaccine trials, sets high bar for success
On a second quarter earnings call, J&J's top scientist said he expects the company's vaccine to significantly surpass the effectiveness standard set out by the FDA.
By Ned Pagliarulo • July 16, 2020 -
Novartis says it won't profit from sale of generic COVID-19 drugs to lower-income countries
The Swiss drugmaker plans to supply 15 medicines — among them the steroid dexamethasone — to as many as 79 nations without taking a profit.
By Kristin Jensen • July 16, 2020 -
Side effects don't stop FDA panel from backing GSK blood cancer drug
An approval decision on what could be a first-in-class multiple myeloma drug is due this month, but the FDA will need to weigh safety concerns against the panel's unanimous support.
By Jonathan Gardner • July 15, 2020 -
Courtesy of AbbVie
AbbVie's 'drip-feed' of patents shields top cancer drug from competition, group says
More than seven dozen patents have been granted for Imbruvica in the U.S., helping AbbVie create a legal defense that could protect the drug until 2036.
By Kristin Jensen • July 15, 2020 -
FDA documents reveal doubts about GSK blood cancer drug
Eye-related side effects could derail the leading drug that homes in on a new multiple myeloma target, just as rival therapies progress toward FDA review.
By Jonathan Gardner • July 10, 2020 -
Big pharma, battling COVID-19, looks to 'buy time' on another health crisis: superbugs
Facing an alarming scarcity of new antibiotics, about two dozen of the world's largest drugmakers are backing a fund meant to develop two to four by 2030.
By Jacob Bell • July 9, 2020 -
Jacob Bell/BioPharma Dive
Merck hits rare FDA setback for cancer drug Keytruda
The regulator declined to grant a speedy approval for Keytruda and Lenvima in liver cancer, citing the recent clearance of another regimen.
By Kristin Jensen • July 8, 2020 -
US buys up early supply of Regeneron's COVID-19 antibody cocktail
A $450 million grant will help Regeneron scale up manufacturing of its drug, which is among the front-running antibody therapies for COVID-19.
By Jonathan Gardner • July 7, 2020 -
J&J, with new deal, plans for long-term manufacture of coronavirus vaccine
A five-year agreement with Maryland's Emergent Biosolutions will provide for large-scale production of J&J's candidate, set to begin testing in July.
By Ned Pagliarulo • July 6, 2020 -
Novartis to pay $678M to settle claims over 'sham' doctor events
The Swiss drugmaker admitted to hosting lavish dinners and events that were intended to convince doctors to prescribe Novartis heart and diabetes drugs.
By Ned Pagliarulo • July 2, 2020 -
AdobeStock/stokkete - Fotolia
Sponsored by ComarchHow to improve document management in the pharma business?
In the near future, many companies within the pharma supply chain will make a step towards EDI in the cloud to increase their productivity, reduce costs, strengthen its own position within the supply chain and achieve many other benefits.
By Mateusz Szarek • July 2, 2020 -
Amgen prevails in high-stakes drug case against Novartis
Novartis, which appealed an earlier court decision upholding two patents on Amgen's Enbrel, indicated it may try to take the case to the Supreme Court.
By Jacob Bell • July 1, 2020 -
Alex Wong via Getty Images
Federal coronavirus contracts dodge pricing oversight, advocacy group says
Contracts with six companies waive "march-in rights" and omit provisions that could be used to object to high drug prices. Moderna's contract, however, includes those clauses.
By Jonathan Gardner • Updated July 1, 2020 -
Permission granted by BioNTech SE
Coronavirus vaccine from Pfizer, BioNTech shows early potential
Initial data from a small study of healthy volunteers show the companies' shot can elicit immune responses against the virus.
By Ned Pagliarulo • July 1, 2020 -
Sponsored by Parexel
COVID-19 and the new pragmatism
What can we learn from the COVID-19 pandemic? What does it mean for the pharmaceutical industry?
By Paul Bridges SVP Worldwide Head Regulatory & Access, Parexel and Sheela Hegde, Partner and Managing Director, Health Advances • June 30, 2020 -
FDA rejects AbbVie's eye drug, citing safety concerns
The drug, abicipar, was supposed to challenge market-leading drugs like Regneron's Eylea. But inner eye inflammation seen in clinical trials appear to have sunk its chances.
By Jacob Bell • June 26, 2020 -
Merck strikes another neuroscience deal, tapping Yumanity for 2 brain drugs
The pharma hasn't invested much in neuroscience since its Alzheimer's drug plans unraveled in 2017. Three deals in the past year, however, should help keep its options open.
By Ben Fidler • June 24, 2020
Previous
